The most common adverse events experienced by patients who received MK-3475 included fatigue, rash, diarrhea, nausea, cough, joint pain, fever and itching. Seven MK-3475 related Grade 3/4 adverse events were reported as potentially “immune related.”Merck recently initiated a global, randomized, Phase II clinical trial to evaluate MK-3475 versus standard chemotherapy for participants with advanced melanoma whose disease has progressed after prior therapy (reference: NCT01704287). Participants will be randomized to receive one of two doses of MK-3475 or investigator-choice chemotherapy. For further information, please visit http://www.clinicaltrials.gov.
Merck Presents Early-Stage Interim Data For MK-3475, An Investigational Therapy For The Treatment Of Advanced Melanoma
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.